Please login to the form below

What does it mean to be an agile organisation

We spoke with Philip Atkinson to learn how healthcare and pharmaceutical companies can rapidly respond to changes in the market.

Traditionally pharmaceutical organisations have been set up in a hierarchical model. Success was achieved by managers knowing more than those below them and by doing this they could control information. However, new theories about organisational change are proving this approach is outmoded. Skills that were once necessary no longer meet the needs of change. To be effective in the future, organisations and individuals need new processes and new skills. Now pharma companies and their agency partners are embracing this change, becoming more agile under a leadership that is increasingly self-aware.

Philip Atkinson is passionate about helping individuals, teams and organisations to grow. He has more than 25 years’ experience in developing high-performing teams at Sanofi, Novartis and Roche. Now, he’s supporting large multinational pharma organisations to become more agile. That’s a question of looking at both processes and people to ensure organisations can quickly respond to market changes. This does not just mean reacting to external pressures. Instead, it’s about pre-empting market change and making sure the company has the tools and behaviours in place to pivot before the pressure reaches to boiling point.

We sat down with Philip to understand his views on what organisational agility means in reality, along with how pharma companies can be more responsive to a more complex and competitive landscape.

Why do pharmaceutical companies typically struggle to be responsive to market changes?

PA: The traditional structure of pharma organisations has been a hierarchical pyramid shape. This can make it difficult to respond quickly to external stimulus and currently there’s a lot of external stimulus for change in the pharma industry. That could be regulatory, it could be from competition, data or pricing. Organisations need to respond to change rapidly – that’s what agility is about. That means having the right structure, the right process and the right people. There are many different models to support this, but you need a common language, a common set of behaviours, skills and support.

It’s also no longer possible to solve all the problems in healthcare from within an organisation. We need to look outwards and be flexible. That might mean in terms of data generation, real-world data, clinical partners, looking at different IT solution, or partnering with different academic institutions.

What scenarios call for organisational change?

PA: There might be pressure to react, for example a takeover threat, a share price drop or a drug safety issue. Often there’s a ‘kick’ that forces you to react. The challenge is to make a change before it’s necessary – that would be a creative change.

Can organisational agility drive innovation?

PA: Innovation comes from better meeting market needs,being curious and having the ability to solve a problem. The more we look outside our organisations, the more open we are to stimulus for innovation. You need to understand what the problems are, you need to have the right inquisitive people, the right resources and the right space in which to be curious. It can be more difficult for innovation to come from within a traditional hierachial structure. External focus is the magic formula.

DOWNLOAD THE FULL ARTICLE HERE

11th July 2019

Share

Tags

Company Details

Blue Latitude Health

+44 203 328 1840

Contact Website

Address:
Blue Latitude Health (UK)
140 Aldersgate Street
London
EC1A 4HY
United Kingdom

Latest content on this profile

In the precision medicine era, the line between products and services is blurred
Precision and personalised medicines are more than products, they are services in their own right. So, how should pharma approach this uncharted territory to ensure targeted therapies work for patients?
Blue Latitude Health
Understanding COVID-19 and varying responses across the globe
At the beginning of the COVID-19 Pandemic, Senior Account Executive Lauren Fernandes took a course at the London School of Hygiene and Tropical Medicine to better understand how the global response to the virus and to ensure we were best positioned to serve our clients during this challenging time. She shares the key learnings and why understanding the epidemiology of the disease is integral for fighting it.
Blue Latitude Health
Top 5 tips for a multi-indication product launch
Senior Associate Consultant Sana Rahim and Senior Consultant Victoria Clark explain the lessons the team has learned from launching six different indications of an oncology product in an accelerated timeframe.
Blue Latitude Health
If our patients are diverse, why are clinical trials so white?
Despite facing worse health outcomes, minority populations are often left out of clinical trials and miss the opportunity to participate in life-saving research. Associate Consultant Ling Song explores this issue and calls for the pharmaceutical industry to change its approach.
Blue Latitude Health
Engaging physicians during COVID-19
COVID-19 has drastically changed the lives of healthcare professionals. They are emotionally and physically drained and under huge amounts of pressure. They also need pharma’s help. Senior Consultant Pany Koizi outlines five principles for engaging with physicians during the pandemic.
Blue Latitude Health
Fishawack Health adds market access and commercial strategy consultancy Skysis as part of its bold growth plans
Fishawack Health, the global healthcare communications agency, announces the acquisition of Skysis, a boutique consulting firm providing integrated market access and commercial strategy solutions based in the US.
Blue Latitude Health